Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight patients lower their weight by 20.7%.

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is rolling out new data on a higher-dose injection in obesity. | In the phase 3b STEP UP study,

Novo Nordisk (NVO) announced Friday that a higher-dose version of its popular obesity therapy, semaglutide, marketed as Wegovy led to 20.7% weight loss over 72 weeks compared to 17.5% weight loss achieved by regular semaglutide in a late-stage trial.